CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

Shares of CRISPR Therapeutics (CRSP) closed at $40.97 on Tuesday, close to their 52-week low of$36.52.This decline in CRSP stock is mainly due to a lack of pipeline updates, which is not sitting well with investors. Also, the company is yet to record revenues from the sales of its sole-marketed product Casgevy, despite it being approved in early 2024.Shares of CRISPR Therapeutics have plunged 43% in the past year compared with the industry’s 7% decline, as seen in the chart below. The stock has also underp ...